According to the Institute of Medicine, chronic pain affects more than 100 million Americans, an incidence rate which outpaces heart disease, cancer and diabetes combined. Neuropathic pain represents ...

Saluda Medical, Inc. (ASX:SLD, "Saluda" or the "Company"), a commercial-stage medical device company focused on developing ...

CARLSBAD, Calif.--(BUSINESS WIRE)--Nalu Medical, Inc (“Nalu”) is a Carlsbad, California-based company that has successfully miniaturized neurostimulation implants for the management of chronic ...

PRETORIA, South Africa, Aug. 1, 2017 /PRNewswire/ -- Xavant Technology (Pty) Ltd today announced that the U.S. Food and Drug Administration (FDA) cleared their Stimpod NMS460. With the U.S. patent ...

Revised Commercial Labeling to Reflect Outcomes of a Randomized Controlled Trial Demonstrating Superiority of DTM™ Spinal Cord Stimulation (SCS) Compared to Conventional SCS for the Treatment of ...

Arizona introduced revisions to a bill that provides protections for patients with chronic intractable pain, which passed unanimously from the Senate Health Committee to the full Senate and will go ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Prospera, a spinal cord stimulation system to treat those with chronic intractable pain in ...

Marlborough medical device manufacturer Boston Scientific Corp. has announced a limited market release of a new pain-relief system that uses electrical impulses in the spine to block pain signals. The ...

Spinal cord stimulation “is effective for some but not for other patients, and effectiveness is usually evaluated in a short trial of a few days to two weeks prior to permanent implantation. Although ...

How Medtronic spinal cord stimulation therapy helped one woman reclaim her life. For more than a decade, Lynnette lived in the shadow of debilitating pain. What began as persistent discomfort in her ...

What I didn’t realize was that my body and emotions were asking me to slow down, to take a deep look within. But I wasn’t listening — until just over 2 years ago when my body screamed. “Isn’t the ...

The parent company behind medical and recreational marijuana dispensary New England Treatment Access has approved $3 million in grants to aid in medical research of cannabis. Parallel, which owns NETA ...